NCT03892720Completed
Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer
A Phase II Study of Non-Coplanar SBRT Re-Irradiation Using HyperArc in Patients With Recurrent Head and Neck Cancer
Source: ClinicalTrials.gov · Last updated 27 Aug 2024
Brief summary (registry, in English)
This phase II trial studies how well stereotactic body radiation therapy with HyperArc software technology works in treating patients with head and neck cancer that has come back. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 33 (actual)
- First submitted
- 26 Mar 2019
- Start date
- 27 Mar 2019
- Primary completion date
- 21 Aug 2024
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Diseases
- Head and neck cancer
- NCT number
- NCT03892720
What you commit to
- Study type: Interventional
- Participants enrolled: 33
- From 27 Mar 2019 to the primary completion date, 21 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Histologically confirmed recurrent head and neck cancer; either unresectable or status post salvage surgery.
- History of radiation therapy for head and neck cancer with minimum 50% overlap of the 50% isodose line from prior treatment to the proposed treatment volume.
- Estimated life expectancy \> 12 weeks.
- Karnofsky performance status \>= 70 (Eastern Cooperative Oncology Group \[ECOG\] 0-2).
- Maximum tumor, or tumor bed, diameter \< 5 cm.
- If a woman is of childbearing potential, a negative serum pregnancy test must be documented. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for duration of study participation and for up to 4 weeks following the study treatment.
- Ability to understand and willingness to sign a written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.